Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Q24245192)

2

0 references

Andrea Berghold

3

0 references

Susanne H Ebrahim

4

0 references

Thomas W Gratzer

5

0 references

Johannes Plank

6

0 references

Thomas Kaiser

7

0 references

Thomas R Pieber

8

0 references

Andrea Siebenhofer

Cochrane Database of Systematic Reviews

9

0 references

language of work or name

English

0 references

publication date

18 April 2007

0 references

published in

0 references

issue

2

0 references

page(s)

CD005613

0 references

cites work

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Benefits of combination therapy of insulin and oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Long-term glycaemic control with insulin glargine in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Effects of mixing glargine and short-acting insulin analogs on glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

The Treat-to-Target Trial and related studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Insulin glargine: an updated review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Hyperglycemia and microvascular and macrovascular disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Risk factors of severe hypoglycaemia in adult patients with Type I diabetes--a prospective population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

7 January 2021

Initiating basal insulin therapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005613.PUB3

7 January 2021

10.1002/14651858.CD005613.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2951624

2951624

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference